Open Veterinary Journal (Sep 2017)

Comparison between fish and linseed oils administered orally for the treatment of experimentally induced keratoconjunctivitis sicca in rabbits

  • Danielle Alves Silva,
  • Gisele Alborgetti Nai,
  • Rogério Giuffrida,
  • Rafael Cabral Barbero,
  • Jacqueline Marcussi Pereira Kuhn,
  • Andressa Caroline da Silva,
  • Ricardo Henrique Zakir Pereira,
  • Maria Fernanda Abbade,
  • Luiz Felipe da Costa Zulim,
  • Carolina Silva Guimarães Pereira,
  • Silvia Franco Andrade

DOI
https://doi.org/10.4314/ovj.v7i3.13
Journal volume & issue
Vol. 7, no. 3
pp. 277 – 285

Abstract

Read online

The objective of this study was to compare the efficacy of two sources of omega 3 and 6, fish oil (FO) and linseed oil (LO), orally administered, alone or in combination, for treating experimentally induced keratoconjunctivitis sicca (KCS) in rabbits. Twenty-eight New Zealand rabbits were used in this study. Seven animals were allocated to the C group (negative control), and KCS was induced in 21 animals by topically applying 1% atropine sulfate drops for 7 days. Treatment with atropine was maintained throughout the study period (12 weeks). The rabbits were divided into 3 treatment groups containing 7 animals each: FO group, LO group and FLO group (FO and LO). The animals were evaluated using the Schirmer Tear Test I (STT I), Rose Bengal Test (RBT), fluorescein test (FT), tear film break-up time (TBUT), and conjunctival and histopathological analysis. There was a significant increase in STT I and TBUT values in treatment groups, but the increase occurred earlier in the FO group. The results of the RBT and FT were similar among treatment groups, except FT, in the FLO group, negative staining was only in 12 weeks. There was a significant decrease in the number of goblet cells in the FLO group compared with the other groups. The results demonstrated that orally administered of FO and LO improved the clinical signs of KCS. However, improvement occurred earlier in the FO group. Using oils in combination did not provide additional benefits. These results contribute to the future development of new oral formulations as adjuvant therapies for KCS.

Keywords